Profile: Vincent Tam

Vincent Tam
Vincent H. Tam, Pharm.D., BCPS (AQ-ID)
Professor
Department of Clinical Sciences and Administration
UH College of Pharmacy
Texas Medical Center Campus, Room 515
Houston, TX 77030

832-842-8316 (phone)
832-842-8383 (fax)
VTam@uh.edu

Education

B.Sc. (Pharm), National University of Singapore, Singapore
Pharm.D., Albany College of Pharmacy, Albany, N.Y.

Post-Doctoral Training

Infectious Diseases Pharmacy Residency, Detroit Receiving Hospital, Detroit, MI
Clinical Pharmacology/Infectious Diseases Fellowship, Albany Medical College, Albany, N.Y.
Board Certified Pharmacotherapy Specialist (with added qualifications in Infectious Diseases)

Research Interests

  • Pharmacokinetics and Pharmacodynamics of antimicrobials
  • Mathematical modeling and simulation of biological processes
  • Mechanisms of bacterial resistance

Awards & Honors

  • American Society of Health-System Pharmacists Best Practices Award, Team Member, Center for Antimicrobial Stewardship and Epidemiology at St. Luke's Episcopal Hospital, 2010 
  • Board of Directors, National Foundation for Infectious Diseases, 2009 to present
  • University of Houston Excellence in Research and Scholarship Award, University of Houston, 2008
  • Best Poster Award, Sixth International Symposium on Antimicrobial Agents and Resistance, 2007
  • Young Investigator Award, Society of Infectious Diseases Pharmacists, 2006
  • Young Investigator Award, American College of Clinical Pharmacy, 2006
  • Faculty Research Excellence Award, University of Houston College of Pharmacy, 2006
  • Resident of the Year, Southeastern Michigan Society of Health-System Pharmacists, 2000

Courses

  • PHAR 5332 Pharmacokinetics
  • PHAR 5403 Pharmacology II
  • PHAR 5581 Advanced Therapeutics I
  • PHAR 5256 Pharmacy Skills Program V
  • PHAR 5681 Infectious Diseases

Selected Publications

He J, Gao S, Hu M, Chow DS, Tam VH. A validated UPLC-MS/MS method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J Antimicrob Chemother 2013; 68(5): 1104-10

Bowers DR, Liew YX, Lye DC, Kwa AL, Hsu LY, Tam VH. Outcome of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2013; 57(3): 1270-4

Hirsch EB, Guo B, Chang KT, Cao H, Ledesma KR, Singh M, Tam VH. Assessment of antimicrobial combinations for KPC-producing Klebsiella pneumoniae. J Infect Dis 2013; 207 (5): 786-93

Tam VH, Chang KT, Yang Z, Newman J, Hu M. In vitro pharmacodynamics of AZD5206 against Staphylococcus aureus. Antimicrob Agents Chemother 2013; 57(2): 1062-4

Abdelraouf K, He J, Ledesma KR, Hu M, Tam VH. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother 2012; 56(11): 5724-7

Verrall AJ, Llorin R, Tam VH, Lye DC, Sulaiman Z, Zhong L, Archuleta S, Fisher DA. Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections. . J Antimicrob Chemother 2012; 67(12): 2970-3

Abdelraouf K, Braggs KH, Yin T, Truong LD, Hu M, Tam VH. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother 2012; 56(9): 4625-9

Belden VS, Hirsch EB, Halfon R, Sirimaturos M, Nguyen PT, Singh R, Liebl MG, Tam VH. Pharmacokinetics of cefepime in critically-ill patients undergoing continuous renal replacement therapy.  TSHP J 2012; 13(2): 5-10 

Tam VH, Hirsch EB, Lasco TM, Gentry LO, Palmer HR. Correlation of hospital carbapenem consumption and resistance trends in selected Gram-negative bacteria. Ann Pharmacother 2012; 46(7-8): 1120-2

Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH. In vitro activity of MK-7655, a novel beta-lactamase inhibitor, in combination with imipenem against carbapenem resistant Gram-negative bacteria. Antimicrob Agents Chemother 2012; 56(7): 3753-7

Tiong CT, Chen C, Zhang SJ, Li J, Soshilov A, Denison MS, Lee Soon-U L, Tam VH, Wong SP, Xu HE, Yong EL. A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ERα protein. Carcinogenesis 2012; 33(5): 1089-97

Tran TT, Palmer HP, Weston J, Hirsch EB, Shah DN, Cottreau J, Tam VH, Garey KW. Evaluation of a daptomycin dose optimization protocol: a potential policy for antibiotic stewardship programs. Am J Health Syst Pharm 2012; 69(11): 979-84

Bhagunde P, Chang KT, Hirsch EB, Ledesma KR, Nikolaou M, Tam VH. A novel modeling framework to guide design of optimal dosing strategies for beta-lactamase inhibitors. Antimicrob Agents Chemother 2012; 56(5): 2237-40

Singh R, Swick MC, Ledesma KR, Yang Z, Hu M, Zechiedrich L, Tam VH. Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob Agents Chemother 2012; 56(4): 1680-5

Guo B, Abdelraouf K, Ledesma KR, Nikolaou M, Tam VH. Predicting bacterial fitness cost associated with drug resistance. J Antimicrob Chemother 2012; 67(4): 921-7

Hirsch EB, Cottreau JM, Chang KT, Caeiro JP, Johnson ML, Tam VH. A model to predict mortality following Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2012 Jan;72(1):97-102.

Palmer HR, Weston J, Gentry L, Salazar M, Putney K, Frost C, Tipton JA, Cottreau J, Tam VH, Garey KW. Improving patient care through implementation of an antimicrobial stewardship program. Am J Health Syst Pharm. 2011 Nov 15;68(22):2170-4.

Singh R, Tam VH. Optimizing dosage to prevent emergence of resistance - lessons from in vitro models. Curr Opin Pharmacol. 2011 Oct;11(5):453-6.

Guo B, Abdelraouf K, Ledesma KR, Chang KT, Nikolaou M, Tam VH. Quantitative impact of neutrophils on bacterial clearance in a murine pneumonia model. Antimicrob Agents Chemother. 2011 Oct;55(10):4601-5.

Tam VH, Cao H, Ledesma KR, Hu M. In-vitro potency of various polymyxin B components. Antimicrob Agents Chemother 2011; 55(9): 4490-1

Abdelraouf K, Kabbara S, Ledesma KR, Poole K, Tam VH. Effect of multidrug resistance-conferring mutations on the biofitness and virulence of Pseudomonas aeruginosa. J Antimicrob Chemother 2011; 66(6): 1311-7

Bhagunde P, Singh R, Ledesma KR, Chang KT, Nikolaou M, Tam VH. Modeling biphasic killing of fluoroquinolones: optimal design of dosing regimens. J Antimicrob Chemother 2011; 66(5): 1079-86

Kwa AL, Abdelraouf K, Low JGH, Tam VH. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin Infect Dis 2011; 52(10): 1280-1

Kwa AL, Falagas ME, Michalopoulos A, Tam VH. Benefits of aerosolized colistin for ventilator associated pneumonia: absence of proof versus proof of absence? Clin Infect Dis 2011; 52(10): 1278-9

Salvatore CM, Abdelraouf K, Hsing DD, Tam VH. Pharmacokinetics of polymyxin B in an infant with multi-drug resistant Klebsiella pneumoniae. Pediatr Infect Dis J 2011; 30(6): 537-9

Tam VH, Nikolaou M. A novel approach to pharmacodynamic characterization of antimicrobial agents: new insights to dosing regimen design. PLoS Comput Biol 2011; 7(1): e1001043

Hirsch EB, Chang KT, Lasco TM, Caeiro JP, Tam VH. Emergence of KPC-producing Klebsiella pneumoniae in Texas. Diagn Microbiol Infect Dis 2011; 69(2): 234-5

Bhagunde P, Chang KT, Singh R, Singh V, Garey KW, Nikolaou M, Tam VH. Mathematical modeling to characterize the inoculum effect. Antimicrob Agents Chemother 2010; 54(11): 4739-43

Garey KW, Jiang ZD, Ghantoji S, Tam VH, Arora V, DuPont HL. A common polymorphism in the interleukin-8 gene promoter is associated with increased risk for recurrent Clostridium difficile infection. Clin Infect Dis 2010; 51(12): 1406-10

Singh R, Ledesma KR, Chang KT, Tam VH. The impact of recA on levofloxacin exposure-related resistance development. Antimicrob Agents Chemother 2010; 54(10): 4262-8

Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. Impact of multidrug resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother 2010; 54(9): 3717-22

Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res 2010; 10(4): 441-51

Palmer HR, Cottreau JM, Garey GW, Hirsch EB, Musick WL, Tam VH, Yeh RF. Significant Publications in Infectious Diseases Pharmacotherapy in 2009. Am J Health Syst Pharm 2010 Aug;67(15):e34-42. Review.

Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010; 65(6): 1119-25

Tam VH, Chang KT, Abdelraouf K, Brioso CG, Ameka M, McCaskey LA, Weston JS, Caeiro JP, Garey KW. Prevalence, mechanism and susceptibility of multidrug resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010; 54(3): 1160-4

Hsu LY, Tan TY, Tam VH, Kwa AL, Fisher DA, Koh TH. Surveillance and correlation of antibiotic prescription and gram-negative resistance in Singapore hospitals. Antimicrob Agents Chemother 2010; 54(3): 1173-8

He J, Figueroa DA, Lim TP, Chow DS, Tam VH. Stability of polymyxin B sulfate diluted in 0.9% sodium choliride injection and stored at 4 or 25°C. Am J Health Syst Pharm 2010; 67(14): 1191-4

He J, Ledesma KR, Lam WY, Figueroa DA, Lim TP, Chow DS, Tam VH. Variability of polymyxin B major components in commercial formulations. Int J Antimicrob Agents 2010; 35(3): 308-10

Yuan Z, Ledesma KR, Singh R, Hou JG, Prince RA, Tam VH. Quantitative assessment of combination antimicrobial therapy against multi-drug resistant bacteria in a murine pneumonia model. J Infect Dis 2010; 201(6): 889-97

Xu H, Kulkarni KH, Singh R, Yang Z, Wang SWJ, Tam VH, Hu M. Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Mol Pharm 2009;6(6): 1703-15

Ingram PR, Lye DC, Fisher DA, Goh WP, Tam VH. Nephrotoxicity of continuous versus intermittent vancomycin infusion in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents 2009; 34(6): 570-4

Kuper KM, Hirsch EB, Tam VH. Significant publications on infectious diseases pharmacotherapy in 2008. Am J Health Syst Pharm 2009; 66(19): 1726-34

Singh R, Ledesma KR, Chang KT, Hou JG, Prince RA, Tam VH. Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model. J Antimicrob Chemother 2009; 64(3): 556-62

Tam VH, Ledesma KR, Schilling AN, Lim TP, Yuan Z, Ghose R, Lewis RE. In-vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection following sub-optimal dosing. Diagn Microbiol Infect Dis 2009; 64(4): 427-33

Tam VH, Ledesma KR, Chang KT, Wang TY, Quinn JP. Killing of Escherichia coli by beta-lactams at different inocula. Diagn Microbiol Infect Dis 2009; 64(2): 166-71

Tam VH, Hou JG, Kwa AL, Prince RA. Comment on: development and validation of a reverse-phase high-performance liquid chromatography assay for polymyxin B in human plasma. J Antimicrob Chemother 2009; 63(3): 627-8

Tam VH, Chang KT, Schilling AN, LaRocco MT, Gentry LO, Garey KW. Impact of AmpC over-expression on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis 2009; 63(3): 279-85

Garey KW, Vo QP, Lewis RE, Saengcharoen W, LaRocco MT, Tam VH. Increased bacterial adherence and biomass in Pseudomonas aeruginosa bacteria exposed to clarithromycin. Diagn Microbiol Infect Dis 2009; 63(1): 81-6

Editorial Board Appointments

  • Board Member, Antimicrobial Agents and Chemotherapy
  • Associate Editor, Journal of Global Antimicrobial Resistance

Professional Service & Affiliations

  • American College of Clinical Pharmacy
  • American Society for Microbiology
  • Infectious Diseases Society of America
  • International Society of Anti-infective Pharmacology
  • Society of Infectious Diseases Pharmacists